dc.contributor.author | Levine, Myron M | |
dc.contributor.author | Abdullah, Salim | |
dc.contributor.author | Arabi, Yyaseen M. | |
dc.contributor.author | Darko, Delese Mimi | |
dc.contributor.author | Durbin, Anna P | |
dc.contributor.author | Estrada, Vicente | |
dc.contributor.author | Jamrozik, Euzebiusz | |
dc.contributor.author | Kremsner, Peter G | |
dc.contributor.author | Lagos, Rosanna | |
dc.contributor.author | Pitisuttithum, Punnee | |
dc.contributor.author | Plotkin, Stanley A | |
dc.contributor.author | Sauerwein, Robert | |
dc.contributor.author | Shi, Sheng-Li | |
dc.contributor.author | Sommerfelt, Halvor | |
dc.contributor.author | Subbarao, Kanta | |
dc.contributor.author | Treanor, John J | |
dc.contributor.author | Vrati, Sudhanshu | |
dc.contributor.author | King, Deborah | |
dc.contributor.author | Balasingam, Shobana | |
dc.contributor.author | Weller, Charlie | |
dc.contributor.author | Aguilar, Anastazia Older | |
dc.contributor.author | Cassetti, M. Cristina | |
dc.contributor.author | Krause, Philip R | |
dc.contributor.author | Restrepo, Ana Maria Henao | |
dc.date.accessioned | 2022-03-01T07:04:58Z | |
dc.date.available | 2022-03-01T07:04:58Z | |
dc.date.created | 2022-01-25T12:37:09Z | |
dc.date.issued | 2021 | |
dc.identifier.issn | 1058-4838 | |
dc.identifier.uri | https://hdl.handle.net/11250/2981897 | |
dc.description.abstract | WHO convened an Advisory Group (AG) to consider the feasibility, potential value, and limitations of establishing a closely-monitored challenge model of experimental severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19) in healthy adult volunteers. The AG included experts in design, establishment, and performance of challenges. This report summarizes issues that render a COVID-19 model daunting to establish (the potential of SARS-CoV-2 to cause severe/fatal illness, its high transmissibility, and lack of a “rescue treatment” to prevent progression from mild/moderate to severe clinical illness) and it proffers prudent strategies for stepwise model development, challenge virus selection, guidelines for manufacturing challenge doses, and ways to contain SARS-CoV-2 and prevent transmission to household/community contacts. A COVID-19 model could demonstrate protection against virus shedding and/or illness induced by prior SARS-CoV-2 challenge or vaccination. A limitation of the model is that vaccine efficacy in experimentally challenged healthy young adults cannot per se be extrapolated to predict efficacy in elderly/high-risk adults. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Oxford University Press | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-monitored Challenge Model of Coronavirus Disease 2019 (COVID-19) in Healthy Volunteers | en_US |
dc.type | Journal article | en_US |
dc.type | Peer reviewed | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright The Author(s) 2020 | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 2 | |
dc.identifier.doi | 10.1093/cid/ciaa1290 | |
dc.identifier.cristin | 1989429 | |
dc.source.journal | Clinical Infectious Diseases | en_US |
dc.source.pagenumber | 2035-2041 | en_US |
dc.identifier.citation | Clinical Infectious Diseases. 2021, 72 (11), 2035-2041. | en_US |
dc.source.volume | 72 | en_US |
dc.source.issue | 11 | en_US |